Bristol-Myers Squibb is trading 4.17% down at $58.60 after Leerink Partners downgraded it from Outperform to Market Perform and cut its price target from $73 to $59 on October 5. - Leerink cited uncertainty around upcoming results for admilparant and milvexian, as well as commercial hurdles for Cobenfy. - Investing.com reported that the downgrade and pipeline concerns weighed on shares in premarket trading. The market snapshot was mixed, and no trading-volume data was provided.